Evidence map›Paper›PMID 27841759›Full record

Trial reportThe Journal of clinical investigation2016

Early pregnancy vitamin D status and risk of preeclampsia.

Hooman Mirzakhani, Augusto A Litonjua, Thomas F McElrath, George O'Connor, Aviva Lee-Parritz, Ronald Iverson, George Macones, Robert C Strunk, Leonard B Bacharier, Robert Zeiger and 13 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of clinical investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00920621 (Randomized Trial), which is not on this map. Cited by 101 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 8 pooled it
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00920621 phase3completednot on this map

Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)

TypeinterventionalSponsorBrigham and Women's HospitalRan2009 to 2023Enrolled876ConditionsAsthmaArmsVitamin D 3 cholecalciferol, Vitamin D3
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 8 syntheses or guidelines pooled it, 204 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Hooman Mirzakhani
Augusto A Litonjua
Thomas F McElrath
George O'Connor
Aviva Lee-Parritz
Ronald Iverson
George Macones
Robert C Strunk
Leonard B Bacharier
Robert Zeiger
Bruce W Hollis
Diane E Handy
Amitabh Sharma
Nancy Laranjo
Vincent Carey
Weilliang Qiu
Marc Santolini
Shikang Liu
Divya Chhabra
Daniel A Enquobahrie
Michelle A Williams
Joseph Loscalzo
Scott T Weiss
Brigham and Women's Hospital · USPulmonary and Allergy Associates · USPulmonary and Critical Care Associates · USSociety for Maternal-Fetal Medicine · USUniversity of Washington · USWashington University in St. Louis · US

Funding

SYSTEMS APPROACHES TO THE EPIDEMIOLOGY, GENETICS AND GENOMICS OF LUNG DISEASEST32HL007427 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DAWN L DEMEO, Edwin K Silverman · 1985 to 2026
$13.6M
TRANSLATIONAL PHARMACOLOGY COREP50GM107618 · NIGMS · HARVARD MEDICAL SCHOOL · PI GOLAN, DAVID E. · 2014 to 2018
$10.8M
Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood AsthmaU01HL091528 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LITONJUA, AUGUSTO A, WEISS, SCOTT T · 2009 to 2013
$10.0M
RANDOMIZED CONTROLLED TRIAL: VDAART CONTINUATION STUDY - DCC - LEADR01HL091528 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LITONJUA, AUGUSTO A, WEISS, SCOTT T · 2014 to 2018
$9.1M
GPx-3 and Peroxide Flux in the Endothelial CellR37HL061795 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2007 to 2016
$4.3M
Randomized Controlled Trial: VDAART Continuation Study - CCCR01HL091075 · NHLBI · WASHINGTON UNIVERSITY · PI BACHARIER, LEONARD B · 2014 to 2018
$2.1M
NHLBI NIH HHS R01 HL091075NHLBI NIH HHS R01 HL091528NHLBI NIH HHS R37 HL061795NHLBI NIH HHS T32 HL007427NHLBI NIH HHS U01 HL091528NIGMS NIH HHS P50 GM107618
6 · The paper itself

Abstract

backgroundLow vitamin D status in pregnancy was proposed as a risk factor of preeclampsia.

methodsWe assessed the effect of vitamin D supplementation (4,400 vs. 400 IU/day), initiated early in pregnancy (10-18 weeks), on the development of preeclampsia. The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on preeclampsia incidence at trial entry and in the third trimester (32-38 weeks) were studied. We also conducted a nested case-control study of 157 women to investigate peripheral blood vitamin D-associated gene expression profiles at 10 to 18 weeks in 47 participants who developed preeclampsia.

resultsOf 881 women randomized, outcome data were available for 816, with 67 (8.2%) developing preeclampsia. There was no significant difference between treatment (N = 408) or control (N = 408) groups in the incidence of preeclampsia (8.08% vs. 8.33%, respectively; relative risk: 0.97; 95% CI, 0.61-1.53). However, in a cohort analysis and after adjustment for confounders, a significant effect of sufficient vitamin D status (25OHD ≥30 ng/ml) was observed in both early and late pregnancy compared with insufficient levels (25OHD <30 ng/ml) (adjusted odds ratio, 0.28; 95% CI, 0.10-0.96). Differential expression of 348 vitamin D-associated genes (158 upregulated) was found in peripheral blood of women who developed preeclampsia (FDR <0.05 in the Vitamin D Antenatal Asthma Reduction Trial [VDAART]; P < 0.05 in a replication cohort). Functional enrichment and network analyses of this vitamin D-associated gene set suggests several highly functional modules related to systematic inflammatory and immune responses, including some nodes with a high degree of connectivity.

conclusionsVitamin D supplementation initiated in weeks 10-18 of pregnancy did not reduce preeclampsia incidence in the intention-to-treat paradigm. However, vitamin D levels of 30 ng/ml or higher at trial entry and in late pregnancy were associated with a lower risk of preeclampsia. Differentially expressed vitamin D-associated transcriptomes implicated the emergence of an early pregnancy, distinctive immune response in women who went on to develop preeclampsia.

trial registrationClinicalTrials.gov NCT00920621.

fundingQuebec Breast Cancer Foundation and Genome Canada Innovation Network. This trial was funded by the National Heart, Lung, and Blood Institute. For details see Acknowledgments.

Indexed as

Dietary SupplementsAdolescentAdultFemaleHumansIncidencePre-EclampsiaPregnancyPregnancy Trimester, FirstPregnancy Trimester, ThirdRisk FactorsVitamin D25-hydroxyvitamin DVitamin D

Identifiers

PMID27841759
PMCPMC5127689
OpenAlexW2550907688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.